COVID19 F41.2
Conditions
Interventions
Group 1: Psychobiotic (Lactobacillus helveticus Rosell-52 i Bifidobacterium longum Rosell-175 in dose 3x10 9 CFU) for 6 weeks, 1 capsule per day
Group 2: Placebo for 6 weeks, 1 capsule per day
Sponsors
Department of Pediatric Gastroenterology and Metabolic Diseases; Poznan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: - Patient-reported postovid depression or anxiety changes (score = 12 on the HADS-anxiety subscale (HADS-A) and / or on the HADS-depression subscale (HADS-D), - consent to participate in the study
Exclusion criteria
Exclusion criteria: - pregnancy, - severe coexisting diseases (liver cirrhosis, portal hypertension, renal failure, neoplastic diseases, diabetes, connective tissue diseases) and menopause, - previously (pre-covid) diagnosed mental illnesses, psychiatric treatment, - taking psychotropic drugs, stimulating / activating dietary supplements (ginger, guarana, ginseng, melatonin), drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| feeling anxiety and depression (HSCL-90, Hopkins Symptom Checklist) | — |
Secondary
| Measure | Time frame |
|---|---|
| cortisol concentration composition of the intestinal microbiota the concentration of short chain fatty acids in the stool assessment of the concentration of inflammatory cytokines psychological tests HADS, GAD-7 | — |
Countries
Poland
Contacts
Public ContactSlawomira Drzymala-Czyz
Department of Bromatology; Poznan University of Medical Sciences
Outcome results
None listed